People · Operator

Jian-min A. Mao, Ph.D.

Named in public records as an officer, director or promoter · active 2009–2009 · Other Health Care

1
Companies
3
Filings
$8.2M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Vioptix IncOther Health CareSeed$8.2M$70.1M2009
Operator network

Jian-min A. Mao, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

W. Gregory Shearer · 2 companies · 1 sharedW. Gregory ShearerAlex A. Keller, M.D. · 1 companies · 1 sharedAlex A. Keller, M…Alex John Keller, M.D. · 1 companies · 1 sharedAlex John Keller,…Bob John Lash, M.D. · 1 companies · 1 sharedBob John Lash, M.…George A. Gardiner · 1 companies · 1 sharedGeorge A. GardinerJennifer John Hamilton · 1 companies · 1 sharedJennifer John Ham…Jian-min John Mao, Ph.D. · 1 companies · 1 sharedJian-min John Mao…L. John Lloyd · 1 companies · 1 sharedL. John LloydMark A. Lonsinger · 1 companies · 1 sharedMark A. LonsingerMark John Lonsinger · 1 companies · 1 sharedMark John Lonsing…Michael A. Cross · 1 companies · 1 sharedMichael A. CrossScott E. Coleridge · 1 companies · 1 sharedScott E. ColeridgeVictor A. Colunga · 1 companies · 1 sharedVictor A. ColungaVioptix Inc · $8.2M raisedVioptix IncJian-min A. Mao, Ph.D.JP
Jian-min A. Mao, Ph.D. Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Jian-min A. Mao, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
W. Gregory Shearer12
L. John Lloyd11
Jennifer John Hamilton11
Scott E. Coleridge11
Alex John Keller, M.D.11
Mark John Lonsinger11
George A. Gardiner11
Bob John Lash, M.D.11
Alex A. Keller, M.D.11
Michael A. Cross11
Mark A. Lonsinger11
Jian-min John Mao, Ph.D.11
Victor A. Colunga11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.